Iovance Biotherapeutics is a company that makes special medicine to help people with certain types of cancer. Their medicine helps the body's own defense system fight the bad cells in the tumor. They are doing well in the stock market and some people want to buy options, which are like bets on how the price of their stock will change. This company is expected to tell us more about how they are doing in a month. Read from source...

1. The article is titled "Iovance Biotherapeutics's Options Frenzy: What You Need to Know", but it does not provide any concrete information about the options market or the company's performance in relation to its options. Instead, it focuses on the stock price and volume, which are irrelevant for options traders.
2. The article mentions that IOVA is a biotech company working on cancer therapies, but it does not explain how this relates to the options market or why investors would be interested in them. It also fails to mention any potential risks or challenges facing the company or its products.
3. The article uses technical terms such as "RSI readings", "overbought", and "options trades" without providing any context or explanation for what they mean or how they are relevant for options traders. It assumes that the reader already knows these terms and their implications, which is not appropriate for a general audience.
4. The article ends with a promotional message for Benzinga Pro, which is an attempt to sell the reader on a paid subscription service without disclosing any potential conflicts of interest or biases. This is misleading and unethical, as it tries to manipulate the reader into signing up for a service that may not be worth the investment or suitable for their needs.